(Via BusinessWire.) Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that it will host an educational webinar on facioscapulohumeral muscular dystrophy (FSHD) and the Company’s Phase 2 clinical trial of ACE-083 in FSHD patients. The webinar will be led by neuromuscular disease expert, Jeffrey Statland, M.D., M.P.H., and Acceleron management, at 10:00 a.m. EDT on Friday, October 28, 2016.
Dr. Statland is an assistant professor of neurology at the University of Kansas Medical Center with both clinical and research training in neuromuscular diseases. His primary research interest is in FSHD, one of the most prevalent forms of muscular dystrophy, characterized by a progressive loss of muscle strength. During the webinar, Dr. Statland will provide an overview of FSHD, its clinical manifestations and unmet medical need. Acceleron management will provide an overview of ACE-083 and the design of the upcoming Phase 2 clinical trial. At the end of the presentation, Dr. Statland and Acceleron management will be available to answer questions from the call participants.
Participants can access the live conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the Acceleron FSHD Call.
The live webcast can be accessed on the Investors page of the Company’s website at www.acceleronpharma.com.
A replay of the webcast will be available approximately two hours after the event on the Acceleron website.
Read the full press release: Acceleron to Host Educational Webcast on Facioscapulohumeral Muscular Dystrophy (FSHD) with Leading Researcher and Provide Overview of ACE-083 Phase 2 Trial
Leave a Reply